ArticleThe Medical clinics of North America2012
Breast cancer therapies and cardiomyopathy.
Article in The Medical clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Endothelin Receptor Blocker Reverses Breast Cancer-Induced Cardiac Remodeling.JACC. CardioOncology · 2023Article
- The forgotten right ventricle in cardio-oncology.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.Toxicology and applied pharmacology · 2020Article
- Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signaling.BMC cancer · 2020Article
- Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Article
- New Myocyte Formation in the Adult Heart: Endogenous Sources and Therapeutic Implications.Circulation research · 2018Review
- Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.The oncologist · 2016Article
- Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Frontiers in oncology · 2014Review
- Cardiac toxicity of anticancer agents.Current cardiology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The prevalence of chemotherapy-related cardiac disease is increasing and management demands a multidisciplinary approach from cardiologists and oncologists. Pretreatment identification of predisposing risk factors and assessment of cardiac function before and at intervals during and after therapy with cardiotoxic agents are necessary. In clinical practice, surveillance is largely performed using transthoracic echocardiography or multi-gated radionuclide angiography. Imaging strategies that detect cardiac injury before overt left ventricular systolic dysfunction provide an opportunity for early intervention and improved cardiac outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.